Nurse practitioner prescriptive authority is regulated by:
a. The National Council of Sate Board of Nursing
b. The State Board of Nursing for each state
c. The U. S. Drug Enforcement Administration
d. The State Board of Pharmacy - (correct Answer) - b. The State Board of Nursing for each state
Eight Information needed for the prescription - (correct Answer) - 1. Date of prescribing;
2. Name of patient(s);
3. Prescriber's name;
4. Name, strength, and dosage of drug or device;
5. Number of refills, if applicable;
6. Quantity prescribed in weight, volume, or number of units;
7. An indication of whether generic substitution has been authorized by the prescriber;
8. Any change or alteration made to the prescription dispensed on contact with the prescriber must
show a clear audit trail.
Three additional required information for controlled substances - (correct Answer) - 1. Address of the
prescriber and patient;
2. The prescriber's DEA number;
3 Controlled prescriptions shall also comply with all requirements of federal and state controlled
substance laws.
Who oversees the APRN's prescribing of controlled substances?
a. The pharmaceutical board of the state
b. The federal government (DEA)
c. The practice protocols of the hospital
d. Practice agreements - (correct Answer) - b. The federal government (DEA)
The USFDA regulates:
,a. Prescribing of drugs by medical doctors and nurse practitioners
b. The official labeling for all prescription and over-the-counter drugs
c. Off-label recommendations for prescribing
d. Pharmaceutical educational offering - (correct Answer) - b. The official labeling for all prescription and
over-the-counter drugs
Medication agreements or "Pain Medication Contracts" are recommended to be used:
a. Universally for all prescribing for chronic pain
b. For patients who have repeated requests for pain medication
c. When you suspect a patient is exhibiting drug-seeking behavior
d. For patients with pain associated with malignancy - (correct Answer) - a. Universally for all prescribing
for chronic pain
Anaphylactic shock is a:
a. Type I reaction, called immediate hypersensitivity reaction
b. Type II reaction, called cytotoxic hypersensitivity reaction
c. Type III reaction, called immune complex hypersensitivity
d. Type IV reaction, called delayed hypersensitivity reaction - (correct Answer) - a. Type I reaction, called
immediate hypersensitivity reaction
The role of the nurse practitioner with regards to herbal medication is to:
a. Maintain competence in the prescribing of common herbal remedies.
b. Recommend common over-the-counter herbs to patients.
c. Educate patients and guide them to appropriate sources of care.
d. Encourage patients to not use herbal therapy due to the documented dangers. - (correct Answer) - c.
Educate patients and guide them to appropriate sources of care.
Prescribing for women during their childbearing years requires constant awareness of the possibility of:
, a. High risk for developmental disorders in their infants
b. Decreased risk for abuse during this time
c. Possible unknown pregnancy
d. Possibility of drug allergies - (correct Answer) - c. Possible unknown pregnancy
Dysmenorrhea is one of the most common gynecological complaints in young women. The first-line of
drug treatment for this disorder is:
a. Oral contraceptive pills
b. Caffeine
c. NSAIDs
d. Aspirin - (correct Answer) - c. NSAIDs
A medication review of an elderly person's medications involves:
a. Asking the patient to bring a list of current prescription medications to the visit.
b. Having the patient bring all their prescription, over-the-counter, and herbal medications to the visit.
c. Asking what other providers are writing prescriptions for them.
d. All of the above. - (correct Answer) - d. All of the above.
What is this skin condition of child?
a. Impetigo
b. Hand, Foot, and Mouth Disease
c. Allergic/hypersensitive reaction
d. Tinea corporis - (correct Answer) - a. Impetigo
ACE-Is are the drug of choice in treating HTN in diabetic patient because they:
a. improve insulin sensitivity
b. improve renal hemodynamics
c. reduce the production of angiotensin II